ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
Thursday, 10 January 2019 03:06
Jan. 10, 2019 12:00 UTC

ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease

TEL AVIV, Israel--(BUSINESS WIRE)-- ChemomAb, a clinical-stage biopharmaceutical company focused on the development of novel therapies for fibrotic-inflammatory diseases, announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease (NAFLD) patients. The company’s lead investigational drug candidate, CM-101, is targeting the chemokine CCL24, an important driver of fibrotic processes.

The Phase 1b clinical trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in people with nonalcoholic fatty liver disease. Patients will be randomized to receive doses of CM-101 or placebo for 12 weeks followed by a recovery phase.

“The initiation of this clinical trial represents an important step forward in the company’s goal to evaluate the potential of CM-101 to interfere with the progression of NASH and its precursor, NAFLD,” said Adi Mor, CEO of ChemomAb. “The understanding that CCL24 plays a pivotal role in fibrotic and inflammatory diseases paves the way for assessing CM-101, a first-in-class CCL24 neutralizing antibody, in several unmet need fibrotic indications, NASH being one of them. We are eager to advance the clinical program with CM-101 in NASH as well as in the orphan indications primary sclerosing cholangitis and systemic sclerosis.”

About ChemomAb

ChemomAb is a clinical-stage biopharmaceutical company that specializes in the development of proprietary monoclonal antibodies directed towards novel targets for the treatment of fibrotic-inflammatory disorders including NASH as well as orphan indications. The antibodies are designed to treat patients with fibrotic and inflammatory diseases through a novel dual mechanism of action that interferes with fibrosis processes directly as well as attenuates the inflammatory process that supports the fibrotic milieu and disease progression. The leading compound, CM-101, was selected after meticulous testing in a series of pre-clinical animal models simulating human disorders and has shown promising safety and efficacy as well as a novel mechanism of action.


Debbie Burgos
[email protected]

Source: ChemomAb

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!